Omeros Corporation
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Omeros Corporation sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Omeros Corporation: 19 sponsored US clinical trials, 1 recruiting.
Omeros Corporation sponsors 19 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 14 completed. 9 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urinary Tract Stones, with 1 trials.
Top-decile sponsor footprint
Omeros Corporation ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
19 total, page 1 of 1
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
NCT05855083
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
NCT03205995
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
NCT03608033
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
NCT02682407
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
NCT02222545
A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
NCT02132312
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
NCT02074410
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
NCT01952132
Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
NCT01579565
Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
NCT01454063
Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy
NCT01406561
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
NCT01193127
Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones
NCT00857090
Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.
NCT00721695
Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones
NCT00599664
Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy
NCT00624845
Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction
NCT00226772
Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction
NCT00226759
Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction
NCT00245271
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 7 |
| Phase 3 | 9 |
What is open in the Omeros Corporation pipeline
1 recruiting of 19 indexed (5% open); 14 completed (74%).
Phase mix: 9 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Urinary Tract Stones (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Omeros Corporation: open-pipeline peers nationwide
Peers matched on 19 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Omeros Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 trials (± recruiting share)
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Defense and Veterans Center for Integrative Pain Management · 5% recruiting · 19 trials
- DePuy Orthopaedics · 5% recruiting · 38 trials
- Impax Laboratories · 5% recruiting · 19 trials
- Kent State University · 5% recruiting · 19 trials
Related
What to do with this Omeros Corporation page
19 registered trials is a research-attention snapshot, not an endorsement of Omeros Corporation or any single study.
- 1 of Omeros Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urinary Tract Stones is the condition Omeros Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urinary Tract Stones trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Omeros Corporation pipeline card: 19 registered trials from official public datasets.Report a data error.